Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens : data from a real-life setting
- Author
- Sophie Degroote (UGent) , Linos Vandekerckhove (UGent) , Dirk Vogelaers (UGent) and Charlotte Vanden Bulcke (UGent)
- Organization
- Abstract
- Background The use of single-tablet regimens (STRs) in HIV treatment is ubiquitous. However, reintroducing the (generic) components as multi-tablet regimens (MTRs) could be an interesting cost-reducing strategy. It is essential to involve patient-reported outcome measures (PROs) to examine the effects of such an approach. Hence, this study compared PROs of people living with HIV taking an STR versus a MTR in a real world setting. Materials and methods This longitudinal study included 188 people living with HIV. 132 remained on a MTR and 56 switched to an STR. At baseline, months 1-3-6-12-18 and 24, participants filled in questionnaires on health-related quality of life (HRQoL), depressive symptoms, HIV symptoms, neurocognitive complaints (NCC), treatment satisfaction and adherence. Generalized linear mixed models and generalized estimation equations mixed models were built. Results Clinical parameters and PROs of the two groups were comparable at baseline. Neurocognitive complaints and treatment satisfaction did differ over time among the groups. In the STR-group, the odds of having NCC increased monthly by 4,1% as compared to the MTR-group (p = 0.035). Moreover, people taking an STR were more satisfied with their treatment after 6 months: the median change score was high: 24 (IQR 7,5-29). Further, treatment satisfaction showed a contrary evolution in the groups: the estimated state score of the STR-group increased by 3,3 while it decreased by 0,2 in the MTR-group (p = 0.003). No differences over time between the groups were observed with regard to HRQoL, HIV symptoms, depressive symptoms and adherence. Conclusions Neurocognitive complaints were more frequently reported among people on an STR versus MTR. This finding contrasts with the higher treatment satisfaction in the STR-group over time. The long-term effects of both PROs should guide the decision-making on STRs vs. (generic) MTRs.
- Keywords
- Multidisciplinary, GENERIC ANTIRETROVIRAL DRUGS, QUALITY-OF-LIFE, COST-EFFECTIVENESS, DE-SIMPLIFICATION, ADHERENCE, THERAPY, EMTRICITABINE, TENOFOVIR, VALIDATION, EFAVIRENZ
Downloads
-
pone.0262533.pdf
- full text (Published version)
- |
- open access
- |
- |
- 879.10 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8758918
- MLA
- Degroote, Sophie, et al. “Patient-Reported Outcomes among People Living with HIV on Single- versus Multi-Tablet Regimens : Data from a Real-Life Setting.” PLOS ONE, edited by Evy Yunihastuti, vol. 17, no. 1, 2022, doi:10.1371/journal.pone.0262533.
- APA
- Degroote, S., Vandekerckhove, L., Vogelaers, D., & Vanden Bulcke, C. (2022). Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens : data from a real-life setting. PLOS ONE, 17(1). https://doi.org/10.1371/journal.pone.0262533
- Chicago author-date
- Degroote, Sophie, Linos Vandekerckhove, Dirk Vogelaers, and Charlotte Vanden Bulcke. 2022. “Patient-Reported Outcomes among People Living with HIV on Single- versus Multi-Tablet Regimens : Data from a Real-Life Setting.” Edited by Evy Yunihastuti. PLOS ONE 17 (1). https://doi.org/10.1371/journal.pone.0262533.
- Chicago author-date (all authors)
- Degroote, Sophie, Linos Vandekerckhove, Dirk Vogelaers, and Charlotte Vanden Bulcke. 2022. “Patient-Reported Outcomes among People Living with HIV on Single- versus Multi-Tablet Regimens : Data from a Real-Life Setting.” Ed by. Evy Yunihastuti. PLOS ONE 17 (1). doi:10.1371/journal.pone.0262533.
- Vancouver
- 1.Degroote S, Vandekerckhove L, Vogelaers D, Vanden Bulcke C. Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens : data from a real-life setting. Yunihastuti E, editor. PLOS ONE. 2022;17(1).
- IEEE
- [1]S. Degroote, L. Vandekerckhove, D. Vogelaers, and C. Vanden Bulcke, “Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens : data from a real-life setting,” PLOS ONE, vol. 17, no. 1, 2022.
@article{8758918, abstract = {{Background The use of single-tablet regimens (STRs) in HIV treatment is ubiquitous. However, reintroducing the (generic) components as multi-tablet regimens (MTRs) could be an interesting cost-reducing strategy. It is essential to involve patient-reported outcome measures (PROs) to examine the effects of such an approach. Hence, this study compared PROs of people living with HIV taking an STR versus a MTR in a real world setting. Materials and methods This longitudinal study included 188 people living with HIV. 132 remained on a MTR and 56 switched to an STR. At baseline, months 1-3-6-12-18 and 24, participants filled in questionnaires on health-related quality of life (HRQoL), depressive symptoms, HIV symptoms, neurocognitive complaints (NCC), treatment satisfaction and adherence. Generalized linear mixed models and generalized estimation equations mixed models were built. Results Clinical parameters and PROs of the two groups were comparable at baseline. Neurocognitive complaints and treatment satisfaction did differ over time among the groups. In the STR-group, the odds of having NCC increased monthly by 4,1% as compared to the MTR-group (p = 0.035). Moreover, people taking an STR were more satisfied with their treatment after 6 months: the median change score was high: 24 (IQR 7,5-29). Further, treatment satisfaction showed a contrary evolution in the groups: the estimated state score of the STR-group increased by 3,3 while it decreased by 0,2 in the MTR-group (p = 0.003). No differences over time between the groups were observed with regard to HRQoL, HIV symptoms, depressive symptoms and adherence. Conclusions Neurocognitive complaints were more frequently reported among people on an STR versus MTR. This finding contrasts with the higher treatment satisfaction in the STR-group over time. The long-term effects of both PROs should guide the decision-making on STRs vs. (generic) MTRs.}}, articleno = {{e0262533}}, author = {{Degroote, Sophie and Vandekerckhove, Linos and Vogelaers, Dirk and Vanden Bulcke, Charlotte}}, editor = {{Yunihastuti, Evy}}, issn = {{1932-6203}}, journal = {{PLOS ONE}}, keywords = {{Multidisciplinary,GENERIC ANTIRETROVIRAL DRUGS,QUALITY-OF-LIFE,COST-EFFECTIVENESS,DE-SIMPLIFICATION,ADHERENCE,THERAPY,EMTRICITABINE,TENOFOVIR,VALIDATION,EFAVIRENZ}}, language = {{eng}}, number = {{1}}, pages = {{15}}, title = {{Patient-reported outcomes among people living with HIV on single- versus multi-tablet regimens : data from a real-life setting}}, url = {{http://doi.org/10.1371/journal.pone.0262533}}, volume = {{17}}, year = {{2022}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: